Skip to main content
OpenTrials
Completed

NCT Number: NCT05401721

Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis

Current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. To the best of our knowledge, few studies have addressed the association between copeptin and sepsis in cirrhotic patients, however, they were performed on different types of infections. Therefore, we will conduct this study with a focus on it is possible role in patients with SBP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Spontaneous Bacterial Peritonitis

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag Faculty of Medicine

Sohag, 82524, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The diagnosis of liver cirrhosis will be based on clinical data and findings on abdominal ultrasound. The diagnosis of SBP will be based on the presence of at least 250 cells/ml PMNLs in the ascitic fluid, with or without positive ascitic fluid culture in the absence of hemorrhagic ascites and secondary peritonitis

Exclusion criteria

  • Patients with heart failure, coronary insufficiency, advanced chronic respiratory disease, polyuria-polydipsia syndrome and hypotension or shock.
  • Patients with chronic kidney disease treated with hemodialysis before admission.
  • Patients with previous liver or kidney transplantation.
  • Patients with intraabdominal malignancy.
  • Patients with severe infection other than SBP.
  • Patients who had received antibiotics before hospital admission.

Treatment and study plan

Serum copeptin

Diagnostic Test

Blood test

Primary outcomes

  1. compare serum levels of copeptin in cirrhotic patients with and without SBP

    Time frame: 6 months

    compare serum levels of copeptin in cirrhotic patients with and without SBP

Secondary outcomes

  1. assess serum copeptin levels in different stages of cirrhosis and its relationship with kidney and circulatory function

    Time frame: 6 months

    assess serum copeptin levels in different stages of cirrhosis and its relationship with kidney and circulatory function

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jun 2, 2022
Registry last updated
Jun 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.